Interested in specific type?

Filter what you see here

General AML

Quick poll

The impact of leukapheresis on clinical outcomes in patients with AML and…

The impact of leukapheresis on clinical outcomes in patients with AML and hyperleukocytosis, results from a large, retrospective, study

Closes Apr 2, 2020

NPM1,   FLT3

Quick poll

Molecular MRD status as a predictor of outcome in patients with…

Closes Mar 31, 2020

General AML

Quick poll

Transplant using a KIR B donor offers relapse protection to patients with…

Closes Mar 27, 2020

General AML

Quick poll

COVID-19 and EBMT recommendations for patients with hematological…

COVID-19 and EBMT recommendations for patients with hematological malignancies

Closes Mar 26, 2020

General AML

Quick poll

VIALE-A study of venetoclax plus azacitidine meets dual primary endpoints

Closes Mar 25, 2020 , Expert Opinion

General AML

Quick poll

Long-term follow-up from MAvRIC trial

Closes Mar 18, 2020

General AML

Quick poll

Results from a CIBMTR study of patients with MLL-rearranged AML

Results from a CIBMTR study of patients with MLL-rearranged AML

Closes Mar 18, 2020

General AML

Quick poll

Subgroup analysis of outcomes in patients with AML-MRC who achieved…

Closes Mar 17, 2020

General AML

Quick poll

Adding ex vivo chemosensitivity assay to mutational profiling improves the…

Closes Mar 13, 2020

General AML

Quick poll

Does intensifying post-remission chemotherapy improve the outcomes of…

Does intensifying post-remission chemotherapy improve the outcomes of older patients with AML?

Closes Mar 12, 2020

General AML

Quick poll

The benefit of gemtuzumab ozogamicin in patients with AML depends on…

Closes Mar 11, 2020

General AML

Quick poll

The passing of Professor Clara D. Bloomfield: a revolutionary, advancing…

Closes Mar 9, 2020

General AML

Quick poll

Phase III VIALE-C trial | Venetoclax + LDAC fails to show improvement in…

Phase III VIALE-C trial | Venetoclax + LDAC fails to show improvement in OS for newly diagnosed patients with AML who are ineligible for…

Closes Mar 4, 2020

General AML

Quick poll

CAR-T 2020 | Cytopenia in CART — the prolonged threat of infection

Closes Mar 2, 2020

General AML

Quick poll

AML Hub Symposium | How does MRD impact outcome of stem cell…

Closes Mar 2, 2020
A global online portal sharing the latest research and emerging treatment information in acute myeloid leukemia

Latest Medical Information

Latest Congress Coverage

General AML

Long-term follow-up from MAvRIC trial

Mar 18, 2020

Latest Drug Updates

Latest Treatment

Recently updated Licences

Where we are next

46th Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

22nd-25th March, 2020 | Madrid, ES

The AML Hub will be attending the 46th Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Madrid, ES, from the 22nd to the 25th of March, 2020. We will be presenting live coverage via our social media channels, interviewing world-leading experts and providing summaries of key sessions. Stay tuned to follow our first-hand coverage. 

Use the following hashtags on Twitter to join the conversation: #leusm #leukemia #EBMT20

Event Website

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology